SUMMARY
INTRODUCTION
Colorectal cancer (CRC), one of the most common malignant tumors in the digestive system, results in approximately 690,000 deaths annually around the word [1] . Tumor resection followed by adjuvant and neoadjuvant is the current standard therapy for CRC. Due to its expanded therapy and the need for lifelong surveillance, CRC is also one of the most expensive cancers to treat [2] . However, the prognosis of patients with CRC remains poorly understood. Therefore, the research on prognostic markers or potentially valuable tumor suppressor genes should be carried out urgently. The fibulin family, which comprises fibulin-1 to -7, is an old protein family discovered in both worms and humans. Fibulin-5, a 66 kDa glycoprotein, is produced by various cell types and is essential for the formation of elastic fibers [3] . Similar to the functions of other fibulin family members, fibulin-5 plays important roles in cell-to-cell and cell-to-matrix communication and helps to organize and stabilize extracellular matrix (ECM) structures during organogenesis and vasculogenesis [4] . In addition, fibulin-5 contains an integrin-binding ArgGly-Asp (RGD) motif which binds to integrins and mediates endothelial cell adhesion [5] . Previous studies have shown that it is down-regulated in a variety of tumor types, including breast, ovarian [6] , hepatocellular [7] , prostate [8] , bladder [9] , and lung [10] cancers. However, this contrasts with findings in human fibrosarcoma [11] and gastric [12] cancers, suggesting that the actions of this ECM protein are tissue-dependent. The role of fibulin-5 in human CRC has not been reported previously. We hypothesized that fibulin-5 expression may be reduced in human CRC, as in most of the other epithelial malignancies. The present study aimed to determine the expression and localization of fibulin-5 in human CRC across different tumor stages and pathological types. Furthermore, we may disclose that fibulin-5 acts as a valuable tumor marker and inhibits tumor progression in CRC.
MATERIALS AND METHODS

Patients and tissue samples
A total of 31 CRC patients including 23 males and 8 females, who received radical operation in the Department of General Surgery at Beijing Chao-yang Hospital from June 2016 to December 2016 (Table 1) , were included. CRC samples and paired normal tumor-adjacent samples (> 5 cm distance from the margin of the tumor) were collected during the surgery. Fresh tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80°C. This study was approved by the ethics committee of Beijing Chao-yang Hospital, and informed consent was obtained from each patient before surgery.
Western blot
Fibulin-5 (ab66339, abcam, Cambridge, UK) (1:1000) and GAPDH (5174, cst, MA, USA) (1:1000) antibodies were used for immunoblotting assay. Horseradish peroxidase (HRP)-conjugated sheep anti-rabbit secondary antibody (305-035-003, Jackson, CA, USA) were used at a dilution 1:10000 and detected by Millipore ECL (WBKLS0500, Millipore, MA, USA). The intensities of the bands of interest were expressed relative to the GAPDH intensities from the same sample and quantified by Gel Image system ver. 4.00 software (Tanon, China).
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
The primer sequences were as follows: fibulin-5 forward, 5'-TCGCTATGGTTACTGCCAGCA-3'; fibulin-5 reverse, 5'-TTGGCAAGACCTTCCATCGTC-3'; GAPDH forward, 5'-AGAAGGCTGGGGCTCATTTG-3'; GAPDH reverse, 5'-AGGGGCCATCCACAGTCTTC-3'. Total RNA was isolated from tissues using TRIZOL ® reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthetized using the TIANScript RT Kit (TIANGEN, Beijing, CN). The PCR amplification for the quantification of the fibulin-5 mRNA and the GAPDH mRNA was performed using an Applied Biosystems 7500HT Fast Block Real Time PCR system (Thermo Fisher Scientific, Inc). The GAPDH was used as an internal control. All PCR reactions were run in triplicate, and gene expression relative to GAPDH was calculated using the 2 −ΔΔCt method.
Immunohistochemical staining
Formalin-fixed paraffin-embedded tissue sections were subjected to antigen retrieval by treatment with 0.01 M Tris-HCl (pH 9.0), followed by incubation with anti-fibulin-5 (ab202977, abcam, Cambridge, UK). Positively stained areas were measured by average optical density using Image Pro Plus (Media Cybernetics, USA).
Statistical analysis
Results are expressed as mean ± SEM. Significance was established, with the SPSS statistical package for Windows Version 13 (SPSS, Chicago, IL, USA), using a Pearson's chi-squared test, a two-tailed Student's t-test, a Mann-Whitney test or a Pearson's correlation coefficient when appropriate. Differences were considered significant when p < 0.05. 
RESULTS
The expression of fibulin-5 in CRC and paired noncancerous tissues Initially, we tested fibulin-5 expression in 31 pairs of cancerous and paired noncancerous tissues using western blot. In these cases, we found that fibulin-5 expression in CRC tissues was prominently lower than that in paired noncancerous tissues (tumor: 0.297 ± 0.148 vs. nontumor: 0.406 ± 0.142, p < 0.01 by t-test, Figure 1) . Furthermore, all of these CRC tissues and paired noncancerous tissues were subjected to qRT-PCR for fibulin-5 mRNA. The difference of fibulin-5 mRNA levels between cancer and paired noncancerous tissues were the same as protein levels (tumor mean rank: 26.71 vs. nontumor mean rank: 36.29, p < 0.05 by Mann-Whitney test, Figure 2 ). Finally, fibulin-5 was immunolocalized in these specimens. Fibulin-5 localized mostly to the stroma, with little staining in the glandular epithelium ( Figure 3A ). When staining intensity was measured by average optical density using Image Pro Plus, there was a significant reduction in CRC tissues compared to that in paired noncancerous tissues (tumor: 2.62 ± 2.17 vs. nontumor: 9.69 ± 6.12, p < 0.01 by t-test, Figure 3B ). Thus, our data indicate that fibulin-5 is down-regulated in CRC tissues compared with controls.
Clinical significance of fibulin-5 expression in CRC tissues
To investigate the clinical significance of fibulin-5 in CRC, we analyzed the correlation between fibulin-5 ex- pression and clinicopathological parameters. As shown in Table 2 , clinical association analysis using an Independent-Samples t-test and a Pearson's correlation coefficient indicated that the down-regulated expression of fibulin-5 in CRC was evidently correlated with lymph node metastasis (r = -0.452, p = 0.011) and advanced tumor-node-metastasis (TNM) tumor stage (r = -0.531, p = 0.002). Furthermore, low expression of fibulin-5 protein may be associated with blood vessel invasion or lymphatic vessel invasion, but not statistically significant (r = -0.309, p = 0.091). Our results indicate that the reduced expression of fibulin-5 was associated with malignant clinicopathological parameters in CRC.
DISCUSSION
Extracellular matrix (ECM), which is an important component of the tumor microenvironment, provides not only structural support but also physically contextual cell-to-cell and cell-to-matrix communications [13] . The proteins in the ECM are mostly glycoproteins, which include relatively large molecules such as laminins, fibronectins, and elastins. However, smaller ECM proteins like the fibulin family are more important in modulating cell behavior and functions [14] . The fibulins interact with many kinds of ECM components and are involved in fibrogenesis, tissue organogenesis, vasculogenesis, and tumorigenesis [15] . Fibulin-5, found in 1999, is produced by various cell types and is essential for the formation of elastic fibers. Fibulin-5 is initially found to be expressed in the neural crest and embryonic vasculature, while it is impaired in most adult vascular beds [16] . Apart from its elastogenic function, fibulin-5 acts as an adhesion molecule via binding of its RGD motif to a number of integrins, including avb3, avb5, and a9b1 [16] . This reveals a critical role of fibulin-5 as a bridging molecule between cells and ECM. Previous studies have identified fibulin-5 as a driving tumor suppressor in human cancers. Wen Yue et al. reported fibulin-5 suppresses lung cancer invasion by inhibiting MMP-7 expression [10]; Lee YH et al. found that fibulin-5 initiated and enhanced TGF-β-induced epithelial-mesenchymal transition (EMT) in mammary epithelial cells [17] ; Zheng Hu et al. reported that downregulation of fibulin-5 is related to the overexpression of VEGF and MYC in urothelial carcinomas of the bladder [9] . The role of fibulin-5 in tumor initiation and progression is still poorly understood. We hypothesize that the decreased expression of fibulin-5 disrupts the architecture of basement membranes and thereby enhances the ability of tumor cells to migrate and invade through the ECM. Moreover, fibulin-5 induced EMT, through which epithelial cells acquire phenotypes of motile fibroblasts, is a critical process in cancer invasion and metastasis [18] .
CONCLUSION
In our study, we initially detected fibulin-5 expression status in 31 pairs of surgical resected CRC tissues. Our data indicated that the level of fibulin-5 expression in CRC was significantly lower than that in paired noncancerous tissues. Furthermore, fibulin-5 protein was expressed at significantly lower levels in CRC patients with lymph node metastasis and advanced TNM tumor stage. These results suggest that the reduced expression of fibulin-5 is correlated with poor prognostic features in CRC. However, more research needs to be done to discover the function of fibulin-5 in CRC. Altogether, we consider that fibulin-5 may potentially act as a diagnostic and/or prognostic biomarker, and may also be a possible target of preclinical gene therapy in CRC; however, this needs further investigation.
Support:
